This article acknowledges the importance of recent Ebola therapeutics and vaccine breakthroughs but also highlights the importance of infection control, community engagement, and disease surveillance as deciding factors in combating the Ebola crisis in the Democratic Republic of Congo.
Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.
Researchers in Uganda have begun a two-year trial to assess the safety and immune response generated by a new two-dose Ebola vaccine manufactured by Janssen Vaccine and Prevention.
A fourth case of Ebola has been detected in the city of Goma. Healthcare workers in the city are working quickly to contain the spread of the virus throughout Goma.
The source of the second confirmed Ebola case in Goma, Democratic Republic of Congo is still unknown. All of those in contact with the patient before he died are now receiving experimental, but effective vaccines.
As the Democratic Republic of Congo’s Ebola outbreak reaches its anniversary, the number of cases continue to surge. Health officials recorded 41 more cases since the end of last week (July 27), with 12 of those cases reported yesterday (July 29).
A body bag has been designed to prevent further Ebola infections while also taking into account the social and cultural operating envrionment.
Median estimates from the three datasets analyzed suggest at least half of all Ebola virus disease spillover events (possibly as many as 83 percent) have gone undetected.
Researchers developed a new methodology that monitors the number of survivors (adaptive capacity) rather than focusing on the confirmed number of cases (impact).
High levels of neutralizing antibodies didn’t appear in patients’ blood until months after patients left the hospital. This information could be used to establish a benchmark of immune protection after vaccination.